Viral vaccines and viral vectors used in biotherapeutic applications carry the risk of microbial contamination, which must be addressed.
Martin Wisher
Advertisement
Martin Wisher, PHD, is senior director, global head of regulatory affairs for BioReliance at MilliporeSigma.
Articles by Martin Wisher
Advertisement
Latest Updated Articles
Ensuring Viral Safety of Viral Vaccines and VectorsPublished: September 1st 2018 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
A-TEEM: A Novel, Powerful Tool for Evaluating and Monitoring Cell Culture Media
2
CPHI Frankfurt 2025 Highlights Global Pharma Innovation and Manufacturing Leadership
3
AstraZeneca Lupus Treatment Support in EU Opens Door for Self-Administration Options
4
Behind the Headlines Episode 27: Unpacking Mega Deals and R&D Directions
5
